CN107875369A - A kind of Chinese medicine natural drug for treating senile dementia - Google Patents
A kind of Chinese medicine natural drug for treating senile dementia Download PDFInfo
- Publication number
- CN107875369A CN107875369A CN201711376750.9A CN201711376750A CN107875369A CN 107875369 A CN107875369 A CN 107875369A CN 201711376750 A CN201711376750 A CN 201711376750A CN 107875369 A CN107875369 A CN 107875369A
- Authority
- CN
- China
- Prior art keywords
- senile dementia
- chinese medicine
- natural drug
- helicidum
- breviscapinun
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
Abstract
The present invention relates to a kind of Chinese medicine natural drug for treating senile dementia, is made up of following each raw materials by weight：American Ginseng 36, gynostemma pentaphylla 10 20, Hericium erinaceus 15 30, psoralea corylifolia 5 10, Morinda officinalis 5 10, pangolin 5 10, leech 1.5 3, Poria cocos 5 10, ginger 5 10, rattletop 5 10, the achene of Siberian cocklebur 5 10, the root of fangji 5 10, blueberry 5 10, Chinese anise 48, unusual seed 48, ginkgo biloba p.e 0.03 0.09, helicidum 0.025 0.05, Breviscapinun 0.02 0.04.Experiment proves, the Chinese medicine natural drug has anti-oxidant, reduce acetylcholine esterase active, reduce Protein tau phosphorylation, suppress the effects such as neurofibril is degenerated and improvement is remembered, available for treatment senile dementia and other failure of memory illnesss, improve cognitive function of patients, improve patient's activity of daily living, have the characteristics that safe and efficient, convenient to take.
Description
Technical field
The present invention relates to a kind of Chinese medicine natural drug for treating senile dementia.
Background technology
Senile dementia is a kind of nervous system of the progress sexual development of onset concealment the most common are Alzheimer disease
Degenerative disease.Clinically with memory disorders, aphasia, appraxia, agnosia, the infringement of visual space technical ability, perform function obstacle and people
The performance of the generalized dementia such as lattice and behavior change is characterized, and the cause of disease is unknown so far.With the arrival of aging society, suffer from old silly
The old man of slow-witted disease is also more and more, and senile dementia has turned into one of " epidemic disease " on our times.Old dementia patients
Activity of daily living declines, and the people to oneself and surrounding brings endless painful and worried.The average survival time of senile dementia patients
Phase is 5.5 years, the disease is turned into one of main cause of death of modern society the elderly.
Traditional Chinese medicine with organic conception and it is dialectical treat as characteristic, showed in terms for the treatment of senile dementia this systemic disease
Go out some superiority, many experiences are have accumulated in prevention of diseae and treatment by Chinese herbs etc..Also, have now been found that many natural drugs
Also have the function that to treat senile dementia.
The content of the invention
The purpose of the present invention is in view of the shortcomings of the prior art, there is provided a kind of Chinese medicine crude drug for treating senile dementia
Thing.
To achieve these goals, the present invention uses following technical scheme：It is a kind of treat senile dementia Chinese medicine it is natural
Medicine, it is made up of following each raw materials by weight：American Ginseng 3-6, gynostemma pentaphylla 10-20, Hericium erinaceus 15-30, psoralea corylifolia 5-
10th, Morinda officinalis 5-10, pangolin 5-10, leech 1.5-3, Poria cocos 5-10, ginger 5-10, rattletop 5-10, achene of Siberian cocklebur 5-10, the root of fangji
5-10, blueberry 5-10, Chinese anise 4-8, unusual seed 4-8, ginkgo biloba p.e 0.05-0.15, helicidum 0.02-0.06,
Breviscapinun 0.02-0.06.Preparation method is：American Ginseng, gynostemma pentaphylla, Hericium erinaceus, psoralea corylifolia, Morinda officinalis, Poria cocos, ginger, liter
Fiber crops, the achene of Siberian cocklebur, the root of fangji, blueberry add water boiling and extraction 2-3 times of 6-10 times of quality, each 1-1.5 hours, after decoction concentration plus second
Alcohol to alcohol content 60-70vol%, refrigeration is filtered after standing 4-8 hours, is reclaimed ethanol, is spray-dried to obtain extract powder；Pangolin,
Leech adds (20-30 DEG C) of the water normal temperature of 4-8 times of quality to soak 12-24 hours after being ground into coarse powder, is freeze-dried after nanofiltration concentration
And it is ground into freeze-dried powder；Chinese anise, unusual seed squeeze it is oily after, add auxiliary material beta-cyclodextrin inclusion compound, crushed after freeze-drying
Obtain freeze-dried powder；Capsule or tablet is made after extract powder, freeze-dried powder and ginkgo biloba p.e, helicidum, Breviscapinun mixing
Or granule.
It is preferred that in prescription containing the American Ginsengs 5 of following parts by weight, gynostemma pentaphylla 15, Hericium erinaceus 20, psoralea corylifolia 6, Morinda officinalis 8,
Pangolin 6, leech 2, Poria cocos 8, ginger 8, rattletop 6, the achene of Siberian cocklebur 6, the root of fangji 6, blueberry 8, Chinese anise 6, unusual seed 6, ginkgo leaf
Extract 0.1, helicidum 0.04, Breviscapinun 0.04.
Effect of the American Ginseng to nervous system has two-sidedness in this Chinese medicine natural drug, and existing suppression also has excited work
With, but based on excitation, it can improve impaired memory and learning functionality, and with anticonvulsion, anti anoxia, antifatigue
Deng effect；Gynostemma pentaphylla, which has, induces and protects nerve cell, suppresses nerve cell tune and dies, improves memory, anti peroxidation of lipid, guarantor
Protect brain tissue, the anti-ageing effect of waiting for a long time；Hericium erinaceus has anti-oxidant, reduction lipofuscin element deposition；Psoralea corylifolia has protection nerve thin
The effect of born of the same parents；Morinda officinalis has protection nerve cell, adjusts intracerebral monoamine neurotransmitter and antidepressant effect；Pangolin has
Blood viscosity is reduced, improves cerebrovascular effect；Leech has anti-freezing, antithrombotic, has significantly to cerebral ischemia re-pouring injured
Protective effect；Poria cocos, which has, maintains nerve cell mitochondrial function, adjusts the effect of Cytosolic Free Calcium Concentration in Brain Nerve Cells；Ginger has
There is protection nerve cell, improve cholinergic nerve function and suppress the effect of cholinesterase activity；There is rattletop regulation nerve to pass
Matter, protect the effect of nerve cell；The achene of Siberian cocklebur has anti-inflammatory and analgesic effect；The root of fangji has scavenging activated oxygen, mitigates ischemic again
The effect of perfusion injury and protection brain cell；Chinese anise, which has, promotees nerve growth and proliferation function；Blueberry, unusual seed are all
With anti-oxidant, the effect of nerve is protected；Ginkgo leaf has anti-oxidant, regulation Cytosolic Free Calcium Concentration in Brain Nerve Cells, removing intracerebral
The effect of amyloid and protection nerve cell；Helicidum has regulation Cytosolic Free Calcium Concentration in Brain Nerve Cells, and antidepression is made
With；Breviscapinun has the function of regulation intracerebral γ-aminobutyric acid concentration, has obvious protection to make to cerebral ischemia re-pouring injured
With.Pass through the side's of tearing open experiment, it is determined that the compatibility of these medicinal materials, the Chinese medicine natural drug have anti-oxidant, reduction acetylcholine ester
Enzymatic activity, Protein tau phosphorylation is reduced, suppress neurofibril degeneration and improves the effect such as memory, it is silly available for treatment old age
Slow-witted disease and other failure of memory illnesss, improve cognitive function of patients, improve patient's activity of daily living.
Pharmacological tests show that this patent medicine can substantially suppress intracerebral acetylcholine esterase active, improve super oxygen
Compound mutase and activity of glutathione peroxidase, and reduce mda content；This patent medicine can reduce Protein tau phosphorus
Acidifying, suppress neurofibril and degenerate；This patent medicine has improvement memory effect.
The acute toxicity test of the present invention：Rat single oral gavage gives product 125.6g crude drugs/kg dosage of the present invention,
Through 14 days Continuous Observations, rat did not occurred any obvious toxicity, does not occur death yet.Mouse single oral gavage is given
Product 188.2g crude drugs/kg dosage of the present invention, through 14 days Continuous Observations, mouse did not occurred any obvious toxicity, not yet
Occur dead.
Long term toxicity test：Continuous 6 months of rat respectively oral gavage give product 80 of the present invention, 40,20g crude drugs/
Tri- dosage of kgd (40,20,10 times equivalent to people's clinic dosage), to the appearance sign of rat, behavioral activity, body of gland
Secretion, breathing, excrement etc. do not occur abnormal response.It is administered 3 months, 6 months and is discontinued 2 weeks and carries out hematology, blood respectively
It is biochemical, substantially see and histopathological examination, as a result show that rat does not occur any obvious poison pair during whole experiment
Reaction, also has no significant effect to each index examined.
Clinical human's test-meal result shows, this patent medicine can improve cognitive function (including directive force, the memory of patient
Power, computing power, language ability, visual space and operational capability etc.) and activity of daily living (including two parts content：Go to toilet, enter
Eat, wear the clothes, wash and dress, walk and have a bath；Make a phone call, do shopping, preparing for a meal, doing housework, doing washing, using the vehicles, medication and from
Manage economic dispatch).
The beneficial effects of the present invention are：For senile dementia and other failure of memorys condition subject, there is provided a kind of
Safely and effectively medicine, the present invention can improve cognitive function of patients, improve patient's activity of daily living, to improving patient
Quality of life has great significance.
Embodiment
The present invention is by American Ginseng, gynostemma pentaphylla, Hericium erinaceus, psoralea corylifolia, Morinda officinalis, Poria cocos, ginger, rattletop, the achene of Siberian cocklebur, anti-
Oneself, blueberry water extraction, concentration, alcohol precipitation, recovery ethanol, be spray-dried to obtain extract powder；Pangolin, leech water extraction, concentration, freeze-drying
And it is ground into freeze-dried powder；Chinese anise, unusual seed squeeze oily, beta-cyclodextrin inclusion compound, freeze-dried powder are crushed to obtain after freeze-drying；Leaching
Solid pharmaceutical preparation is made after cream powder, freeze-dried powder and ginkgo biloba p.e, helicidum, Breviscapinun mixing to take.It is each by adjusting
Material rate relation so that each raw material realizes preferable synergistic function, i.e., after the combination of several medicinal materials, its drug effect relative to
Increased during exclusive use；Drug effect is more lasting；Produced in treatment senile dementia and other failure of memory illness fields
Unexpected effect.
The invention will be further described in conjunction with the embodiments.
Embodiment 1
The preparation of Chinese medicine natural drug：
Following each raw materials by weight：American Ginseng 3, gynostemma pentaphylla 10, Hericium erinaceus 15, psoralea corylifolia 5, Morinda officinalis 5, Poria cocos
5th, ginger 5, rattletop 5, the achene of Siberian cocklebur 5, the root of fangji 5, blueberry 5, pangolin 5, leech 1.5, Chinese anise 4, unusual seed 4, ginkgo leaf carry
Take thing (standards of pharmacopoeia extract) 0.05, helicidum 0.02, Breviscapinun 0.02.Above ten simply medicinal material add 6 times amount water (68
× 6) extraction 2 times is decocted, 1 hour every time, after decoction concentration plus ethanol was to alcohol content 70% (volume content), and it is small that refrigeration stands 8
When after filter, reclaim ethanol, be spray-dried to obtain extract powder；Pangolin, leech is ground into after coarse powder plus 4 times of amount water (6.5 × 4) are normal
Temperature immersion 12 hours, it is freeze-dried after nanofiltration concentration and is ground into freeze-dried powder；Chinese anise, unusual seed squeeze it is oily after, add
Auxiliary material beta-cyclodextrin inclusion compound, freeze-dried powder is crushed to obtain after freeze-drying；Extract powder, freeze-dried powder and ginkgo biloba p.e, helicidum,
Granule is made after Breviscapinun mixing.
If 4 sample sets, including this patent sample sets, American Ginseng that same procedure obtains, psoralea corylifolia, leech, ginger, indigo plant
The certain kind of berries, ginkgo biloba p.e mixture group, gynostemma pentaphylla, Morinda officinalis, the achene of Siberian cocklebur, rattletop, Chinese anise, helicidum mixture group,
Hericium erinaceus, pangolin, Poria cocos, the root of fangji, unusual seed, Breviscapinun mixture group.
Morris water maze tests, 5 groups of experiment point, blank control group and 4 sample sets are carried out using inbred mouse, often
Group administration one month, blank group gives distilled water.Last dose next day starts to test, and test water temperature stability is at 20 ± 1 DEG C, every group
From 3 different quadrants, respectively test once, tests 1min to animal every time daily, and meter record each group escape latency is (from water is entered to looking for
To the time needed for platform), and average value is calculated, it the results are shown in Table 1.
Jumping test, 6 groups of experiment point, blank control group, model control group and 4 samples are carried out using inbred mouse
Group, every group of administration one month, blank control group and model control group all give distilled water.Next day starts to train after last dose,
Animal is put into reaction chamber to (on platform, under platform) and adapts to environment 3min, then by the copper grid in animal placing response case, immediately
36V alternating currents are passed to, animal is shocked by electricity, and its normal reaction is rebound platform (insulator), most to hide noxious stimulation
Animal may again or be repeatedly skipped on copper grid, snapped back again on platform by electric shock.After training once, animal is placed on instead
Answer on the platform in case, record each mouse in 5min and jump off the errors number of platform and jump off the incubation period of platform for the first time, with this
As school grade.After 24 hours resurvey testing, resurvey the ethanol of 30min model groups and each administration group gavage 30% before testing
10mL/kg BW, mouse is placed on platform during experiment, records each mouse and jump off for the first time in the incubation period and each mouse 5min of platform
Number of shocks.It the results are shown in Table 2.Animal is put to death after off-test and takes out brain tissue to wherein related index, including acetylcholine
Esterase (AchE), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) activity and MDA (MDA) contain
Amount is detected.It the results are shown in Table 3.
Experimental result is shown：The present invention can shorten the time required for water maze test mouse covering the race；Extend and jump
Platform experiment mice gets an electric shock incubation period, reduces electric shock number.The present invention can also significantly reduce AchE activity, notable increased SOD,
GSH-Px activity, and reduce MDA contents.From the results, it was seen that each raw material is through processing in Chinese medicine natural drug of the present invention
Afterwards, there is the function of cooperateing with anti-oxidant, acetylcholine esterase inhibition activity and improve memory.Effect effect of the present invention is more than single-action
Answer sum.
The each group Mice water maze escape latency result of table 1 (N=10)
The each group mouse step down test incubation period of table 2 and electric shock number result (N=10)
Table 3 in mouse brain AchE, SOD, GSH activity and MDA contents influence (N=10)
Embodiment 2：
The preparation of Chinese medicine natural drug：
Following each raw materials by weight：American Ginseng 6, gynostemma pentaphylla 20, Hericium erinaceus 30, psoralea corylifolia 10, Morinda officinalis 10, Fu
Siberian cocklebur 10, ginger 10, rattletop 10, the achene of Siberian cocklebur 10, the root of fangji 10, blueberry 10, Chinese anise 8, unusual seed 8, ginkgo biloba p.e 0.15,
Helicidum 0.06, Breviscapinun 0.06.Above ten simply medicinal material add 10 times of amount water boiling and extractions 3 times, 1.5 hours every time, medicine
After liquid concentration plus ethanol to alcohol content 60%, refrigeration is filtered after standing 4 hours, is reclaimed ethanol, is spray-dried to obtain extract powder；Wear mountain
First, leech is ground into after coarse powder plus 8 times are measured water soak at room temperature 24 hours, is freeze-dried after nanofiltration concentration and is ground into freeze-dried powder；
Chinese anise, unusual seed squeeze it is oily after, add auxiliary material beta-cyclodextrin inclusion compound, freeze-dried powder is crushed to obtain after freeze-drying；Extract powder,
Granule is made after freeze-dried powder and ginkgo biloba p.e, helicidum, Breviscapinun mixing.
If 4 sample sets, including this patent sample sets, American Ginseng that same procedure obtains, psoralea corylifolia, leech, ginger, indigo plant
The certain kind of berries, ginkgo biloba p.e mixture group, gynostemma pentaphylla, Morinda officinalis, rattletop, the achene of Siberian cocklebur, Chinese anise, helicidum mixture group,
Hericium erinaceus, pangolin, Poria cocos, the root of fangji, unusual seed, Breviscapinun mixture group.
AD sample Protein tau phosphorylation rat brain slice models, every rat are prepared using okadaic acid (okadaic acid, OA)
Cut brain piece 6 to open, be randomly divided into 6 groups：Blank control group, model group and 4 sample sets, every group 10 is opened brain piece.Brain piece is not appointed
Where reason is incubated in artificial cerebrospinal fluid after 1h, and sample is added in 4 sample sets nutrient solutions, pre-processes 2h.Model group and each dense
OA is separately added into degree sample sets nutrient solution, it is respectively 1 μm of ol/L to make its concentration, acts on 3h, and blank control group is not added with any place
Reason.Brain piece is taken out from artificial cerebrospinal fluid, 4h is fixed with 4% paraformaldehyde, is then taken out and is transferred to 30% sucrose solution and is dipped to
Sink to the bottom, cook frozen section, 10 μm of slice thick, every section is containing cortex, hippocampus, dentate fascia.Using immunohistochemical staining
(SABC) method detects each group brain piece cortex and hippocampus P-tau, the positive expression situation of Protein tau respectively.
Experimental result is shown：Compared with blank control group, the table of P-tau albumen in model group rats brain piece cortex and hippocampus
Up to increase, the expression of Protein tau is reduced.The present invention can reduce P-tau protein expressions in rat brain slice, increase Protein tau table
Reach.From the results, it was seen that for each raw material after processing, having reduces Protein tau phosphoric acid in Chinese medicine natural drug of the present invention
Change, suppress the effect that neurofibril is degenerated.Effect effect of the present invention answers sum more than single-action.
Influence of the table 4 to P-tau protein expressions
The influence that table 5 is expressed Protein tau
Embodiment 3：
The preparation of Chinese medicine natural drug：
Following each raw materials by weight：American Ginseng 5, gynostemma pentaphylla 15, Hericium erinaceus 20, psoralea corylifolia 6, Morinda officinalis 8, Poria cocos
8th, ginger 8, rattletop 6, the achene of Siberian cocklebur 6, the root of fangji 6, blueberry 8, pangolin 6, leech 2, Chinese anise 6, unusual seed 6, ginkgo leaf extraction
Thing 0.1, helicidum 0.04, Breviscapinun 0.04.Above 13 taste medicinal materials add 8 times to measure water boiling and extraction 2 times, and 1.5 is small every time
When, after decoction concentration plus ethanol to alcohol content 60%, refrigeration is filtered after standing 6 hours, is reclaimed ethanol, is spray-dried to obtain medicinal extract
Powder；Pangolin, leech is ground into after coarse powder plus 6 times are measured water soak at room temperature 18 hours, is freeze-dried and is ground into after nanofiltration concentration
Freeze-dried powder；Chinese anise, unusual seed squeeze it is oily after, add auxiliary material beta-cyclodextrin inclusion compound, freeze-dried powder is crushed to obtain after freeze-drying；
Granule is made after extract powder, freeze-dried powder and ginkgo biloba p.e, helicidum, Breviscapinun mixing.
If 3 sample sets, respectively embodiment 1,2,3 sample, light moderate senile dementia patient 200 is selected,
It is divided into four groups, every group each 50.Four groups of cases, without obvious significant difference, have comparable in sex, age, the course of disease etc.
Property.Administration group oral this product daily, takes 8 weeks.Control group uses merely Donepezil Hydrochloride.
Four groups of patients carry out mini-mental state examination (MMSE) and daily before treatment and after treatment
Viability scale (ADL) scores.Cognitive function (including directive force, memory, computing power, the language energy of MMSE detection patients
Power, visual space and operational capability etc.), ADL is mainly used in evaluating activity of daily living (including two parts content of subject：Body
Body is taken care of oneself scale, is gone to toilet, feeds, wears the clothes, washes and dresses, walks and is had a bath；Instrumental ADL, make a phone call, do shopping, preparing for a meal,
Do housework, do washing, using the vehicles, medication and self-care economic dispatch).The standard of curative effect evaluation：It is 1. effective：Clinical symptoms disappear substantially
Lose, conscious, orientation is accurate, and life can take care of oneself, and can complete daily social activities；It is 2. effective：Main spirits symptom slightly subtracts
Weak or partial disappearance, but life can take care of oneself substantially, and reaction is slightly blunt, and intelligence has a certain degree of obstacle with personality；It is 3. invalid：Disease
Shape is not improved, or even disease progression, can't take care of oneself, and is answered a question incorrect, mental dementia.In terms of effective and be effective
Calculate total effective rate.
As a result show, treated effect and Doneppezil Hydrochloride phase of this patent Chinese medicine natural drug to senile dementia
When the cognitive function and activity of daily living of patient are slightly better than Doneppezil Hydrochloride.
6 four groups of curative effects of table compare
| Group | It is effective | Effectively | It is invalid | Efficient (%) |
| Control group | 12 | 28 | 10 | 80 |
| Embodiment 1 | 9 | 27 | 14 | 72 |
| Embodiment 2 | 11 | 28 | 11 | 78 |
| Embodiment 3 | 14 | 27 | 9 | 82 |
Pretherapy and post-treatment MMSE, ADL scoring of 7 two groups of table is compared
From table 6,7 as can be seen that embodiment 1,2,3 clinically can effectively treat senile dementia, wherein, embodiment
3 (American Ginseng 5, gynostemma pentaphylla 15, Hericium erinaceus 20, psoralea corylifolia 6, Morinda officinalis 8, pangolin 6, leech 2, Poria cocos 8, ginger 8, rattletop 6,
The achene of Siberian cocklebur 6, the root of fangji 6, blueberry 8, Chinese anise 6, unusual seed 6, ginkgo biloba p.e 0.1, helicidum 0.04, Breviscapinun
0.04) effect is optimal.
Above example is used for the explanation and illustration present invention, is not intended to limit the invention, the ordinary skill of art
Personnel should be understood：Still the embodiment of the present invention can be modified or some technical characteristics are equal
Replace, without departing from the spirit of technical solution of the present invention, it all should cover works as in the claimed technical scheme scope of the present invention
In.
Claims (2)
1. a kind of Chinese medicine natural drug for treating senile dementia, it is characterised in that by following each raw material groups by weight
Into：American Ginseng 3-6, gynostemma pentaphylla 10-20, Hericium erinaceus 15-30, psoralea corylifolia 5-10, Morinda officinalis 5-10, pangolin 5-10, leech
It is 1.5-3, Poria cocos 5-10, ginger 5-10, rattletop 5-10, achene of Siberian cocklebur 5-10, root of fangji 5-10, blueberry 5-10, Chinese anise 4-8, strange
Different seed 4-8, ginkgo biloba p.e 0.05-0.15, helicidum 0.02-0.06, Breviscapinun 0.02-0.06.
2. medicine according to claim 1, it is characterised in that the medicine is by following each raw material groups by weight
Into：American Ginseng 5, gynostemma pentaphylla 15, Hericium erinaceus 20, psoralea corylifolia 6, Morinda officinalis 8, pangolin 6, leech 2, Poria cocos 8, ginger 8, rattletop 6,
The achene of Siberian cocklebur 6, the root of fangji 6, blueberry 8, Chinese anise 6, unusual seed 6, ginkgo biloba p.e 0.1, helicidum 0.04, Breviscapinun
0.04。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711376750.9A CN107875369A (en) | 2017-12-19 | 2017-12-19 | A kind of Chinese medicine natural drug for treating senile dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711376750.9A CN107875369A (en) | 2017-12-19 | 2017-12-19 | A kind of Chinese medicine natural drug for treating senile dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107875369A true CN107875369A (en) | 2018-04-06 |
Family
ID=61771015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711376750.9A Pending CN107875369A (en) | 2017-12-19 | 2017-12-19 | A kind of Chinese medicine natural drug for treating senile dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107875369A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101029064A (en) * | 2007-04-11 | 2007-09-05 | 昆明贝克诺顿制药有限公司 | Bean-curd pectin analogues, and its use in preparation of medicine for preventing senile dementia |
| CN103393705A (en) * | 2013-07-05 | 2013-11-20 | 昆明医科大学 | Application of scutellarin in preparing medicines for preventing and treating Alzheimer's disease |
| CN104258193A (en) * | 2014-10-17 | 2015-01-07 | 云南省林业科学院 | Drug composition for treating neurasthenia and preventing senile dementia |
-
2017
- 2017-12-19 CN CN201711376750.9A patent/CN107875369A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101029064A (en) * | 2007-04-11 | 2007-09-05 | 昆明贝克诺顿制药有限公司 | Bean-curd pectin analogues, and its use in preparation of medicine for preventing senile dementia |
| CN103393705A (en) * | 2013-07-05 | 2013-11-20 | 昆明医科大学 | Application of scutellarin in preparing medicines for preventing and treating Alzheimer's disease |
| CN104258193A (en) * | 2014-10-17 | 2015-01-07 | 云南省林业科学院 | Drug composition for treating neurasthenia and preventing senile dementia |
Non-Patent Citations (2)
| Title |
|---|
| 戴光强: "《医学继续教育系列丛书 中医临床粹要（进展篇）》", 30 April 2001, 安徽科学技术出版社 * |
| 陈会君: "《中医内科学教学医案选编》", 28 February 2015, 中国中医药出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zahiruddin et al. | Ashwagandha in brain disorders: A review of recent developments | |
| Lokanathan et al. | Recent updates in neuroprotective and neuroregenerative potential of Centella asiatica | |
| Kanter et al. | Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats | |
| Joshi et al. | Pharmacological evidences for antiamnesic potentials of Phyllanthus amarus in mice | |
| CN105920476B (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and preparation method thereof | |
| Inanaga | Amycenone, a nootropic found in Hericium erinaceum | |
| CN111686173A (en) | Application of agilawood extract | |
| Joseph et al. | Physalis minima L. Fruit-A Promising Approach To Alzheimer's Disease | |
| US11278584B2 (en) | Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof | |
| CN103070927A (en) | New usages of lotus plumule and alkaloid thereof and derivative thereof | |
| CN104721732B (en) | A kind of herbal composite for treating senile dementia | |
| CN107875369A (en) | A kind of Chinese medicine natural drug for treating senile dementia | |
| Njan | Herbal medicine in the treatment of malaria: Vernonia amygdalina: an overview of evidence and pharmacology | |
| Moharir et al. | Evaluation of hepatoprotective effect of hydroalcoholic extract of Momordica charantia leaves in carbon tetrachloride-induced liver toxicity in Wistar rats | |
| Pakadang et al. | Subcronic Toxicity and Hepatoprotector Potential of Miana Leaf Extract on White Rat Which Indicated by Anti Tuberculosis Drugs. | |
| KR101509056B1 (en) | Composition having brain function and congnition enhancing activity comprising ginseng mixed herbal extracts, ginsenoside Rg2 and ginsenoside F2 | |
| Prasad et al. | Neuroprotective Effect of Ginkgo Biloba and its | |
| CN100545163C (en) | A kind of active ingredient of Chinese herbs compound and preparation and purposes of preventing and treating senile dementia | |
| Nawaz et al. | Evaluation of acute and repeated dose toxicity of the polyherbal formulation linkus syrup in experimental animals | |
| WO2014038878A2 (en) | Composition for brain-neuron protection and brain-disease prevention, alleviation or treatment comprising muskrat musk | |
| Dodamani et al. | Antidiabetic efficacy of ethanolic leaf extract of Nymphaea odorata in Alloxan induced Diabetic mice | |
| CN102138982B (en) | Compound valeriana amurensis composition for treating senile dementia, and preparation method and application thereof | |
| KR20170096586A (en) | Composition for preventing, improving or treating stress or depression comprising medicinal herb extract as effective component | |
| Ajmalhussain | Assessment of the Neuro-Protective Effects of Combination of Acorus Calamus and Eugenol in Alzheimer’s Animal Model | |
| Mohammadi et al. | Investigating the Effects of Ellagic Acid on Thioacetamide-Induced Acute Liver Damage and Subsequent Encephalopathy in Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180406 |
|
| RJ01 | Rejection of invention patent application after publication |